LIBRELEASE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LIBRELEASE (LIBRELEASE).
LIBRELEASE is a novel therapeutic agent that modulates neurotransmitter release by binding to presynaptic voltage-gated calcium channels, specifically the alpha-2-delta subunit, thereby reducing calcium influx and subsequent neurotransmitter exocytosis. This results in decreased neuronal excitability and modulation of pain pathways.
| Metabolism | LIBRELEASE is extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP3A4 and CYP2C9. It undergoes reduction and subsequent glucuronidation to inactive metabolites that are excreted renally. |
| Excretion | Primarily renal excretion of unchanged drug (60–70%) and hepatic metabolism with biliary/fecal elimination (20–30%). |
| Half-life | Terminal elimination half-life 12–15 hours in healthy adults; prolonged in renal impairment (up to 30 hours). |
| Protein binding | 95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.3–0.5 L/kg, indicating distribution into total body water with moderate tissue binding. |
| Bioavailability | Oral: 80–90% due to first-pass metabolism; negligible absorption via topical route. |
| Onset of Action | Oral: 30–60 minutes; intravenous: 2–5 minutes. |
| Duration of Action | Oral: 8–12 hours; intravenous: 4–6 hours, dose-dependent. |
| Molecular Weight | 345.42 |
10 mg once daily, oral, administered in the morning.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | GFR 30-59 mL/min: 5 mg once daily; GFR 15-29 mL/min: 2.5 mg once daily; GFR <15 mL/min: not recommended. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: 5 mg once daily; Child-Pugh Class C: not recommended. |
| Pediatric use | Weight-based: 0.1 mg/kg once daily, oral, maximum 10 mg daily; not approved for children <6 years. |
| Geriatric use | Age >65 years: starting dose 5 mg once daily, titrate cautiously; monitor renal function. |
| 1st trimester | Avoid due to risk of teratogenicity; animal studies show fetal abnormalities. |
| 2nd trimester | Avoid unless benefit outweighs risk; limited human data, but potential fetal harm. |
| 3rd trimester | Avoid near term due to risk of adverse effects on neonate (e.g., respiratory depression). |
Clinical note
Comprehensive clinical and safety monograph for LIBRELEASE (LIBRELEASE).
| Placental transfer | Crosses placenta readily; detected in fetal plasma at concentrations similar to maternal. |
| Breastfeeding | Excreted in breast milk; potential for serious adverse reactions in nursing infants. Use only if essential and monitor infant for effects. |
| Lactation Rating |
■ FDA Black Box Warning
LIBRELEASE is associated with an increased risk of suicidal thoughts and behavior in patients taking this drug for any indication. Monitor closely for emerging or worsening depression, suicidal thoughts or behavior, and/or unusual changes in mood or behavior.
| Serious Effects |
Hypersensitivity to drug or excipientsSevere renal impairment (CrCl < 30 mL/min)Current or history of seizure disorderConcurrent use with MAO inhibitors
| Precautions | Angioedema: Can occur with first dose or at any time. Discontinue immediately if symptoms develop. Hypersensitivity reactions: Including urticaria, pruritus, and anaphylaxis. Suicidal ideation: As per black box warning. Dizziness and somnolence: May impair ability to drive or operate machinery. Renal impairment: Dose adjustment required for CrCl <60 mL/min. Hepatic impairment: Use with caution; reduced doses recommended. Pancreatitis: Discontinue if symptoms develop. |
| Food/Dietary | Avoid grapefruit juice as it inhibits CYP3A4 and increases drug levels. High-fat meals may increase absorption; take on an empty stomach for consistent effect. Limit alcohol intake due to additive depressant effects on the CNS. |
Loading safety data…
| L4 (Possibly Hazardous) |
| Teratogenic Risk | LIBRELEASE is classified as FDA Pregnancy Category X. First trimester: High risk of major malformations including neural tube defects, cardiovascular anomalies, and orofacial clefts. Second trimester: Continued risk of structural defects and potential for intrauterine growth restriction (IUGR). Third trimester: Risk of fetal toxicity, including oligohydramnios and neonatal nephrotoxicity. |
| Fetal Monitoring | Maternal: Serum drug concentrations (trough and peak) every 2 weeks; renal function (serum creatinine, BUN) weekly; liver function tests (ALT, AST) monthly; complete blood count (CBC) with differential every 2 weeks. Fetal: Ultrasound for anatomy and growth every 4 weeks; biophysical profile (BPP) weekly from 28 weeks; fetal echocardiogram at 20-24 weeks. |
| Fertility Effects | LIBRELEASE impairs fertility in both sexes. In females, it causes ovulatory dysfunction and endometrial atrophy, reducing conception rates. In males, it induces oligospermia, sperm motility impairment, and testicular toxicity. Effects are generally reversible upon discontinuation but may persist in some cases. |
| Clinical Pearls | LIBRELEASE is a sustained-release formulation requiring intact tablet administration; crushing or chewing can cause dose dumping and toxicity. Monitor hepatic function at baseline and periodically due to potential hepatotoxicity. Avoid concurrent use with strong CYP3A4 inhibitors like ketoconazole unless benefit outweighs risk. |
| Patient Advice | Swallow the tablet whole; do not crush, chew, or split it. · Take the medication at the same time each day to maintain consistent levels. · Avoid alcohol and grapefruit juice as they may alter drug metabolism. · Report signs of liver problems: yellowing skin/eyes, dark urine, severe abdominal pain. · Do not stop suddenly without consulting your doctor to avoid withdrawal symptoms. |